ROI For Biomedical Research Slipping

As more money has been spent on biomedical research in the United States over the past 50 years, there has been diminished return on investment in terms of life expectancy gains and new drug approvals, two Johns Hopkins Bloomberg School of Public Health researchers say. In a report published Aug. 17 in the Proceedings of the National Academy of Sciences, the researchers found that while the number of scientists has increased more than nine-fold since 1965 and the National Institutes of Health's budget has increased four-fold, the number of new drugs approved by the Food and Drug Administration has only increased a little more than two-fold. Meanwhile, life expectancy gains have remained constant at roughly two months per year. read more

Read the whole article on

More from